Jardiance, a Diabetes Drug, Cut Cardiovascular Deaths by 38%, Study Says
In a clinical trial, the drug reduced the risk of having a heart attack or stroke, or of dying from cardiovascular causes by 14 percent.
Source: NYT Health - Category: Consumer Health News Authors: ANDREW POLLACK Tags: Johnson & Johnson JNJ NYSE Heart Drugs (Pharmaceuticals) Eli Lilly and Company LLY NYSE Stroke Merck Company Inc MRK NYSE Diabetes Boehringer Ingelheim GmbH Source Type: news
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Empagliflozin | Endocrinology | Health | Heart | Heart Attack | Jardiance | Merck | Stroke | Study